High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Lin, Yueh Min ^a,b,c   Sung, Wen Wei ^b,c,d   Hsieh, Ming Ju ^a,b   Tsai, Shih Chen ^b   Lai, Hung Wen ^a,e   Yang, Shu Mei ^f   Shen, Ko Hong ^a   Chen, Mu Kuan ^a   Lee, Huei ^f   Yeh, Kun Tu ^a,b   Chen, Chih Jung ^a,b,c  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ALCOHOL CONSUMPTION; ARTICLE; BETEL QUID CHEWING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SEX DIFFERENCE; SMOKING; SUBSTANCE USE; SURVIVAL RATE; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; FOLLOW UP; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 84955495338     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142656     Document Type: Article

References (39)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. (2015) Global cancer statistics, 2012. CA Cancer J Clin.
2. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5-29. doi: 10.3322/caac.21254 PMID: 25559415
3. Greenberg JS, El Naggar AK, Mo V, Roberts D, Myers JN (2003) Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 98:508-515. PMID: 12879467
4. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T, et al. (2003) Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg 185:278-284. PMID: 12620571
5. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9-22. doi: 10.1038/nrc2982 PMID: 21160525
6. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, et al. (2005) Novel markers for poor prognosis in head and neck cancer. Int J Cancer 113:789-797. PMID: 15499618
7. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274. PMID: 15776005
8. Greaves P, Gribben JG (2013) The role of B7 family molecules in hematologic malignancy. Blood 121:734-744. doi: 10.1182/blood-2012-10-385591 PMID: 23223433
9. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, et al. (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102. PMID: 1335364
10. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219-242. doi: 10.1111/j.1600-065X.2010.00923.x PMID: 20636820
11. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:562-567. PMID: 12704383
12. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203:883-895. PMID: 16606670
13. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704. doi: 10.1146/annurev. immunol.26.021607.090331 PMID: 18173375
14. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793-800. PMID: 12091876
15. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111:3635-3643. doi: 10.1182/blood-2007-11-123141 PMID: 18223165
16. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10:5094-5100. PMID: 15297412
17. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11:2947-2953. PMID: 15837746
18. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. (2003) B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63:6501-6505. PMID: 14559843
19. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. (2004) Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101:17174-17179. PMID: 15569934
20. Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, et al. (2003) Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63:7462-7467. PMID: 14612546
21. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. (2006) The B7-H1 (PDL1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8:190-198. PMID: 16611412
22. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC (2014) Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50:1361-1369. doi: 10.1016/j.ejca.2014.01.018 PMID: 24548766
23. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66:3381-3385. PMID: 16585157
24. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13:2151-2157. PMID: 17404099
25. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra137.
26. Ferrand F, Malka D, Bourredjem A, Allonier C, Bouche O, Louafi S, et al. (2013) Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Federation Francophone de Cancerologie Digestive 9601. Eur J Cancer 49:90-97. doi: 10.1016/j.ejca.2012.07.006 PMID: 22926014
27. Chen CJ, Sung WW, Lin YM, Chen MK, Lee CH, Lee H, et al. (2012) Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma. PLoS One 7:e50104. doi: 10.1371/journal. pone.0050104 PMID: 23185547
28. Chen CJ, Sung WW, Su TC, Chen MK, Wu PR, Yeh KT, et al. (2013) High expression of interleukin 10 might predict poor prognosis in early stage oral squamous cell carcinoma patients. Clin Chim Acta 415:25-30. doi: 10.1016/j.cca.2012.09.009 PMID: 22981868
29. Sung WW, Lin YM, Wu PR, Yen HH, Lai HW, Su TC, et al. (2014) High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients. BMC Cancer 14:951. doi: 10. 1186/1471-2407-14-951 PMID: 25511643
30. Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang L, et al. (2011) A polymorphic-844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res 17:5991-5999. doi: 10.1158/1078-0432. CCR-11-0227 PMID: 21807637
31. Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC, et al. (2013) IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res 19:4092-4103. doi: 10.1158/1078-0432. CCR-12-3439 PMID: 23743567
32. Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21 Suppl 7:vii252-261. doi: 10.1093/annonc/mdq453 PMID: 20943624
33. Strome SE, Sausville EA, Mann D (2007) A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 12:1084-1095. PMID: 17914078
34. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. (2013) Cetuximabactivated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 19:1858-1872. doi: 10.1158/1078-0432. CCR-12-2426 PMID: 23444227
35. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465. doi: 10.1056/NEJMoa1200694 PMID: 22658128
36. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454. doi: 10. 1056/NEJMoa1200690 PMID: 22658127
37. Ribas A (2012) Tumor immunotherapy directed at PD-1. N Engl J Med 366:2517-2519. doi: 10.1056/NEJMe1205943 PMID: 22658126
38. Swanson MS, Sinha UK (2015) Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current data. Oral Oncol 51:12-15. doi: 10.1016/j. oraloncology.2014.10.010 PMID: 25459157
39. Gildener-Leapman N, Ferris RL, Bauman JE (2013) Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 49:1089-1096. doi: 10.1016/j.oraloncology.2013.09.009 PMID: 24126223